Index -
P/E -
EPS (ttm) -1.92
Insider Own 26.30%
Shs Outstand 51.65M
Perf Week 5.38%
Market Cap 253.43M
Forward P/E -
EPS next Y -1.85
Insider Trans 3.03%
Shs Float 38.11M
Perf Month 0.20%
Income -82.44M
PEG -
EPS next Q -0.43
Inst Own 69.42%
Short Float 4.76%
Perf Quarter 63.88%
Sales 0.00M
P/S -
EPS this Y 7.98%
Inst Trans 0.10%
Short Ratio 3.02
Perf Half Y 70.73%
Book/sh 2.26
P/B 2.17
EPS next Y -7.17%
ROA -52.37%
Short Interest 1.81M
Perf Year 169.23%
Cash/sh 2.54
P/C 1.93
EPS next 5Y -
ROE -70.94%
52W Range 1.43 - 6.85
Perf YTD 74.38%
Dividend Est. -
P/FCF -
EPS past 5Y -49.79%
ROI -59.34%
52W High -28.47%
Beta 2.64
Dividend TTM -
Quick Ratio 6.82
Sales past 5Y 0.00%
Gross Margin -
52W Low 242.66%
ATR (14) 0.43
Dividend Ex-Date -
Current Ratio 6.82
EPS Y/Y TTM 23.34%
Oper. Margin 0.00%
RSI (14) 54.03
Volatility 11.17% 9.34%
Employees 54
Debt/Eq 0.22
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.60
Option/Short Yes / Yes
LT Debt/Eq 0.19
EPS Q/Q 35.12%
Payout -
Rel Volume 0.67
Prev Close 5.09
Sales Surprise -
EPS Surprise 27.04%
Sales Q/Q -
Earnings Mar 12 BMO
Avg Volume 600.99K
Price 4.90
SMA20 5.19%
SMA50 16.65%
SMA200 48.56%
Trades
Volume 404,260
Change -3.73%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-14-23 Initiated
Piper Sandler
Overweight
Jun-30-23 Upgrade
Stifel
Hold → Buy
$2 → $10
Jun-28-23 Upgrade
H.C. Wainwright
Neutral → Buy
$11
Jun-27-23 Upgrade
Wedbush
Neutral → Outperform
$10
Mar-29-22 Downgrade
Wedbush
Outperform → Neutral
Mar-22-22 Downgrade
H.C. Wainwright
Buy → Neutral
Sep-30-21 Initiated
Stifel
Hold
$10
Jan-07-21 Initiated
Wedbush
Outperform
$45
Nov-24-20 Initiated
Berenberg
Buy
$58
May-04-20 Initiated
H.C. Wainwright
Buy
$53
Feb-24-20 Initiated
JP Morgan
Overweight
$42
Feb-24-20 Initiated
Jefferies
Buy
Feb-24-20 Initiated
Cowen
Outperform
Feb-24-20 Initiated
Canaccord Genuity
Buy
$50
Show Previous Ratings
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
(Associated Press Finance) -5.50%
08:00AM
Mar-05-24 04:30PM
08:00AM
Loading…
Feb-28-24 08:00AM
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
(Associated Press Finance)
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
12:34PM
Loading…
Sep-18-23 12:34PM
(American City Business Journals)
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
(Associated Press Finance)
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
08:00AM
Loading…
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
(American City Business Journals)
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Jan-11-22 07:00AM
Jan-10-22 07:00AM
Jan-05-22 08:00AM
Nov-18-21 05:27AM
Nov-08-21 04:05PM
07:45AM
Oct-08-21 04:05PM
Oct-04-21 11:02AM
Sep-30-21 04:35PM
Sep-21-21 04:05PM
07:45AM
Aug-12-21 08:22AM
Aug-10-21 07:45AM
Aug-04-21 07:45AM
Aug-02-21 02:26AM
Jul-29-21 03:53PM
May-19-21 05:00PM
May-17-21 07:45AM
May-07-21 07:45AM
May-04-21 02:01AM
Apr-28-21 10:38AM
Apr-10-21 08:30AM
Mar-25-21 07:45AM
Mar-10-21 04:58PM
Mar-02-21 04:05PM
Feb-23-21 07:45AM
Feb-11-21 04:15PM
Feb-02-21 11:51PM
07:32PM
Jan-20-21 07:45AM
Jan-05-21 07:45AM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIOTECH GROWTH N V 10% Owner Oct 17 '23 Buy 2.34 400,000 934,080 8,517,839 Oct 19 03:08 PM Behbahani Ali Director Jul 05 '23 Buy 5.00 1,000,000 5,000,000 4,448,757 Jul 06 04:45 PM RA CAPITAL MANAGEMENT, L.P. Director Jul 05 '23 Buy 5.00 935,850 4,679,250 3,213,828 Jul 07 04:30 PM BIOTECH GROWTH N V 10% Owner Jun 30 '23 Buy 5.00 1,000,000 5,000,000 8,117,839 Jul 03 03:36 PM BIOTECH GROWTH N V 10% Owner Jun 27 '23 Buy 5.49 1,740,000 9,555,036 7,117,839 Jun 29 01:37 PM Epstein David M. SEE REMARKS Jun 27 '23 Sale 6.70 25,000 167,500 671,423 Jun 28 04:02 PM
Index -
P/E -
EPS (ttm) -1.97
Insider Own 5.21%
Shs Outstand 80.04M
Perf Week -3.81%
Market Cap 5.91B
Forward P/E -
EPS next Y -4.08
Insider Trans -3.10%
Shs Float 79.80M
Perf Month -21.27%
Income -153.61M
PEG -
EPS next Q -1.45
Inst Own 64.27%
Short Float 18.45%
Perf Quarter 7.39%
Sales 371.21M
P/S 15.91
EPS this Y -199.14%
Inst Trans -0.05%
Short Ratio 7.48
Perf Half Y 52.99%
Book/sh 23.52
P/B 2.98
EPS next Y 29.75%
ROA -6.87%
Short Interest 14.72M
Perf Year 61.55%
Cash/sh 20.12
P/C 3.49
EPS next 5Y -
ROE -8.17%
52W Range 37.55 - 91.10
Perf YTD 12.08%
Dividend Est. -
P/FCF -
EPS past 5Y 10.83%
ROI -7.29%
52W High -22.99%
Beta 1.76
Dividend TTM -
Quick Ratio 17.54
Sales past 5Y 33402.13%
Gross Margin 65.88%
52W Low 86.84%
ATR (14) 3.35
Dividend Ex-Date -
Current Ratio 17.54
EPS Y/Y TTM 76.72%
Oper. Margin -53.64%
RSI (14) 39.07
Volatility 3.37% 4.18%
Employees 407
Debt/Eq 0.13
Sales Y/Y TTM 30885.48%
Profit Margin -41.38%
Recom 2.28
Target Price 85.74
Option/Short Yes / Yes
LT Debt/Eq 0.12
EPS Q/Q 177.83%
Payout -
Rel Volume 0.68
Prev Close 70.97
Sales Surprise 42.76%
EPS Surprise 1559.13%
Sales Q/Q 3353333.33%
Earnings Feb 21 BMO
Avg Volume 1.97M
Price 70.16
SMA20 -8.52%
SMA50 -4.14%
SMA200 18.52%
Trades
Volume 1,340,687
Change -1.14%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Dec-11-23 Downgrade
TD Cowen
Market Perform → Underperform
$30
Oct-17-23 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Sep-27-23 Initiated
Mizuho
Buy
$82
Aug-17-23 Upgrade
Citigroup
Neutral → Buy
May-30-23 Initiated
William Blair
Outperform
$75
Apr-13-23 Initiated
Cantor Fitzgerald
Overweight
$72
Mar-21-23 Initiated
Bernstein
Mkt Perform
$44
Mar-17-23 Initiated
Bryan Garnier
Buy
$70
Mar-07-23 Initiated
Robert W. Baird
Neutral
$46
Oct-11-22 Initiated
Morgan Stanley
Underweight
$37
Aug-09-22 Downgrade
Barclays
Overweight → Equal Weight
$99 → $88
Jun-23-22 Downgrade
Evercore ISI
Outperform → In-line
$66 → $60
Jun-17-22 Initiated
BMO Capital Markets
Outperform
$98
Apr-28-22 Initiated
Credit Suisse
Neutral
$78
Dec-07-21 Initiated
Cowen
Market Perform
Oct-19-21 Initiated
SVB Leerink
Outperform
$126
Jun-14-21 Upgrade
Citigroup
Sell → Neutral
$55 → $132
Apr-21-21 Upgrade
Jefferies
Hold → Buy
$172
Mar-04-21 Initiated
JMP Securities
Mkt Outperform
$160
Show Previous Ratings
Mar-27-24 04:50AM
Mar-25-24 06:15PM
Mar-24-24 10:08AM
Mar-23-24 06:45AM
Mar-22-24 11:30AM
04:19PM
Loading…
Mar-21-24 04:19PM
Mar-20-24 01:49PM
Mar-19-24 06:15PM
12:07AM
Mar-17-24 08:50AM
Mar-16-24 08:45AM
Mar-14-24 08:15AM
Mar-13-24 02:25PM
08:30AM
Mar-06-24 02:45PM
06:53PM
Loading…
Mar-05-24 06:53PM
Mar-04-24 11:02AM
08:48AM
Feb-29-24 05:32PM
06:31AM
05:50AM
Feb-27-24 12:00PM
Feb-26-24 08:50AM
06:45AM
Feb-23-24 10:01AM
Feb-22-24 07:37AM
04:00AM
Feb-21-24 04:32PM
(Investor's Business Daily)
10:15AM
(Investor's Business Daily)
07:30AM
05:02AM
Loading…
Feb-20-24 05:02AM
Feb-19-24 04:08PM
01:45AM
Feb-16-24 02:19PM
07:31AM
Feb-15-24 08:30AM
Feb-14-24 08:15AM
Feb-13-24 01:22PM
(Investor's Business Daily)
10:00AM
08:30AM
02:30AM
Feb-10-24 05:09PM
Feb-09-24 06:00PM
Feb-08-24 02:59AM
Feb-07-24 10:00AM
09:09AM
Feb-05-24 08:00AM
Feb-04-24 02:35PM
Feb-02-24 06:00PM
Feb-01-24 09:10PM
Jan-31-24 12:28PM
Jan-30-24 05:10AM
05:02AM
Jan-28-24 05:10AM
Jan-25-24 06:15PM
08:32AM
Jan-24-24 09:45AM
Jan-23-24 09:30AM
Jan-22-24 09:12AM
05:05AM
Jan-21-24 09:37AM
08:00AM
Jan-20-24 06:50AM
Jan-19-24 06:15PM
Jan-16-24 04:08PM
(Investor's Business Daily)
04:01PM
08:15AM
Jan-15-24 04:56PM
06:30AM
05:19AM
Jan-14-24 01:30PM
05:10AM
Jan-13-24 06:05AM
05:20AM
Jan-10-24 06:00AM
Jan-09-24 06:15PM
Jan-08-24 09:17AM
07:00AM
05:00AM
Jan-06-24 05:00AM
Jan-04-24 05:00AM
Jan-03-24 12:17PM
08:30AM
Jan-01-24 09:05AM
Dec-31-23 10:30AM
08:45AM
Dec-30-23 06:50AM
12:09AM
Dec-25-23 05:30AM
Dec-22-23 05:02PM
05:27AM
Dec-21-23 08:30AM
05:51AM
Dec-20-23 11:04AM
(FierceBiotech.com) -9.01%
09:43AM
05:00AM
Dec-19-23 05:11PM
(The Wall Street Journal) +8.84%
05:00AM
Dec-18-23 05:30AM
Dec-17-23 08:45AM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kulkarni Samarth Chief Executive Officer Mar 15 '24 Option Exercise 19.12 20,000 382,400 228,122 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 15 '24 Sale 72.48 20,000 1,449,628 208,122 Mar 18 05:45 PM Prasad Raju Chief Financial Officer Mar 15 '24 Sale 72.69 3,524 256,160 6,476 Mar 18 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 12 '24 Sale 74.44 4,583 341,159 208,122 Mar 12 05:45 PM KASINGER JAMES R. General Counsel and Secretary Mar 12 '24 Sale 74.44 1,146 85,308 61,174 Mar 12 05:45 PM Kulkarni Samarth Chief Executive Officer Mar 11 '24 Sale 78.26 9,802 767,105 203,705 Mar 12 05:45 PM KASINGER JAMES R. General Counsel and Secretary Mar 11 '24 Sale 78.26 2,801 219,206 60,070 Mar 12 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 20 '24 Sale 79.67 6,370 507,498 194,257 Feb 21 05:45 PM KASINGER JAMES R. General Counsel and Secretary Feb 20 '24 Sale 79.67 1,913 152,409 57,371 Feb 21 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 15 '24 Option Exercise 19.12 20,000 382,400 207,377 Feb 16 05:45 PM Kulkarni Samarth Chief Executive Officer Feb 15 '24 Sale 80.36 20,000 1,607,177 187,377 Feb 16 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 29 '24 Option Exercise 19.12 50,000 956,000 237,377 Jan 31 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 29 '24 Sale 60.51 50,000 3,025,573 187,377 Jan 31 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 16 '24 Option Exercise 19.12 20,000 382,400 207,377 Jan 18 05:45 PM Kulkarni Samarth Chief Executive Officer Jan 16 '24 Sale 62.50 20,000 1,250,058 187,377 Jan 18 05:45 PM Kulkarni Samarth Chief Executive Officer May 30 '23 Option Exercise 19.12 25,000 478,000 412,377 Jun 01 05:44 PM Kulkarni Samarth Chief Executive Officer May 30 '23 Sale 64.88 25,000 1,621,894 387,377 Jun 01 05:44 PM Kulkarni Samarth Chief Executive Officer Apr 25 '23 Option Exercise 19.12 25,000 478,000 412,377 Apr 27 05:37 PM Kulkarni Samarth Chief Executive Officer Apr 25 '23 Sale 50.67 25,000 1,266,638 387,377 Apr 27 05:37 PM Kulkarni Samarth Chief Executive Officer Mar 29 '23 Option Exercise 19.12 25,000 478,000 412,377 Mar 31 05:49 PM Kulkarni Samarth Chief Executive Officer Mar 29 '23 Sale 44.46 25,000 1,111,504 387,377 Mar 31 05:49 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite